Explore our products, services, and solutions that are at the center of clinical decision-making and treatment pathways.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Investor Relations
  3. Press releases, Ad-hocs & Related Party Transactions
Investor relations

Press releases, Ad-hocs & Related Party Transactions

Save the date
Fourth-quarter results and

preliminary figures for fiscal year

November 3, 2021 Online

Latest press releases

Start of the European FAST III study: Angio-derived assessment of blood flow in diseased coronary arteries
Erlangen, Germany
The first patients were recently enrolled in the FAST III trial at the Erasmus University Medical Center in Rotterdam, The Netherlands. This officially marked the beginning of a multicenter, randomized-controlled, open-label study in which the outcome of therapy for coronary artery disease is being investigated after fractional flow reserve has been determined using different methods

Siemens Healthineers accelerating growth and launching “New Ambition” – the third phase of its Strategy 2025
Erlangen, Germany
“With fiscal year 2022 we started the next chapter of strategy 2025. We call this chapter New Ambition, and it will be about an ever-accelerating stream of breakthrough innovations and of accelerated growth,” said Bernd Montag, CEO of Siemens Healthineers AG.

Ad-hoc announcements & Related Party Transactions